Na urticaria, e kilai levu me hives, e dua na mate ni kuli e dau basika kina na vuvuce, tubu cake, kei na dromodromo ena kuli.
Na pathophysiology ni urticaria e okati kina na kena sereki na histamine kei na so tale na ka e vakavuna na kama mai na mast cell, na sela ni yago e dau taqomaka na yago e kune ena kuli kei na so tale na tikiniyago.
Ena gauna e dau basika kina na mate oqo, e dau vakabulabulataki na histamine kei na so tale na ka e vakavuna na kena lako vakaca e dua na ka e dau lako vakaca, me vaka na kakana, wainimate, se na kati ni manumanu lalai.
Na ka oqo e vakavuna me sega ni vakalevutaki na levu ni sela e tiko ena uro ni manumanu, e vakavuna me basika na histamine kei na so tale na ka e vakavuna me drodro na dra, e vakavuna me buli kina na wheals.
E sega ni kilai na vuna e tauvi koya tiko kina, ia e nanumi ni vakavuna na kena dewa ena yago.
Ena ituvaki oqo, na yago e bulia na autoantibodies e taketetaki kina na IgE receptor (FcεRI) ena mast cell, e vakavuna me vakabulabulataki kina na histamine kei na so tale na ka e dau vakavuna na mate.
Ena gauna ni urticaria, e dau lako tani na histamine kei na so tale na ka e vakavuna na vutu, damudamu, kei na vuvuce ni yago.
E dau vakayagataki na antihistamines me tarova na kena cakacaka qai vakamamadataka na kena ivakatakilakila.
Ena so na ituvaki dredre, e rawa ni vakayagataki e so tale na wainimate me vaka na corticosteroid se omalizumab me tarova na mate.
Wahlgren CF: Pathophysiology of itching in urticaria and atopic dermatitis. Allergy. 1992, 47 (2 Pt 1): 65-75.
Raap U, Liekenbröcker T, Wieczorek D, Kapp A, Wedi B: [New therapeutic strategies for the different subtypes of urticaria]. Hautarzt. 2004, 55 (4): 361-6.
[Recommendations for the diagnosis and treatment of urticaria in children]. Arch Argent Pediatr. 2021, 119 (2): S54-S66.
Brzoza Z, Grzeszczak W, Rogala B, Trautsolt W, Moczulski D: Possible contribution of chemokine receptor CCR2 and CCR5 polymorphisms in the pathogenesis of chronic spontaneous autoreactive urticaria. Allergol Immunopathol (Madr). , 42 (4): 302-6.
Sweeney TM, Dexter WW: Cholinergic urticaria in a jogger: ruling out exercise-induced anaphylaxis. Phys Sportsmed. 2003, 31 (6): 32-6.
['iVakamacala: veiqaravi vakavuniwai']
['Na website qo e vakarautaki me baleta ga na vuli kei na itukutuku, e sega ni kena inaki me soli kina na ivakasala vakavuniwai se veiqaravi vakavuniwai.']
['Na itukutuku e vakarautaki e sega ni dodonu me vakayagataki me dikevi kina se me qaravi kina e dua na mate, o ira tale ga na via qara ivakasala vakavuniwai mera lai raici vuniwai.']
['Me nanumi tiko ni neural network e dau vakarautaka na isaunitaro e sega ni dau donu ena gauna e cakacakataki kina na iwiliwili, me vaka na kedra iwiliwili na tauvimate.']
['Ke o nanuma ni o tauvimate bibi, qirita na 911 se gole ina vanua ni veiqaravi e voleka vei iko. E sega ni dua na veiwekani e tauyavutaki ena website qo se na kena vakayagataki. E sega ni dua na ka e tukuna se cakava na BioMedLib se o ira na kena tamata cakacaka, se o ira na vakaitavi ena website qo me baleta na itukutuku e tiko kina se na kena vakayagataki.']
['Disclaimer: dodonu ni lavelavetaki']
['Na Digital Millennium Copyright Act ni 1998, 17 U.S.C. § 512 (na DMCA) e vakarautaka na recourse me baleta na itaukei ni dodonu ni lavelavetaki era vakabauta ni iyaya e basika ena Initaneti e voroka na nodra dodonu ena ruku ni lawa ni dodonu ni lavelavetaki ni Amerika. ']
['Ke o vakabauta ni dua na ka e tabaki ena neimami website se na neimami veiqaravi e beci kina na nomu dodonu ni kena maroroi na itukutuku, o iko (se nomu mata) e rawa ni o vakauta mai e dua na notisi mo kerea me kau laivi se me tarovi na kena vakayagataki. ']
['Me vakau na itukutuku ena i-meli (raica na "Veitaratara" ena tabana e baleta na itikotiko ni imeli). ']
['Na DMCA e gadrevi kina na nomu itukutuku ni kena beitaki ni beci na dodonu ni lavelavetaki e oka kina na itukutuku oqo: (1) ivakamacala ni cakacaka ni taqomaki ni dodonu ni lavelavetaki e tukuni ni sa beci; (2) ivakamacala ni lewena e beitaki ni beci kei na itukutuku e veirauti me rawa kina ni da kunea na lewena; (3) itukutuku ni veitaratara me baleti iko, oka kina na nomu itikotiko, naba ni talevoni kei na itikotiko ni imeli; (4) e dua na itukutuku mai vei iko ni o vakabauta ena vakabauta vinaka ni lewena ena kena ivakarau e kudruvaka e sega ni vakadonui mai vua na itaukei ni dodonu ni lavelavetaki, se na kena mata, se ena cakacaka ni dua na lawa; ']
['(5) e dua na nomu ivakamacala, e sainitaki ena itotogi ni bubului lasu, ni dina na itukutuku e volai ena notisi, ni tu tale ga vei iko na dodonu mo valataka na dodonu ni kena taqomaki na ka e volai; ']
['E sega ni dodonu me dua na ka e caka ena kena vakayagataki na Internet.']
['Ke o sega ni vola na itukutuku kece qori, ena rawa ni berabera na kena qaravi na nomu kudru.']
['Veitaratara']
['Yalovinaka vakauta mai na imeli ena dua na taro se vakatutu.']
What is pathophysiology of urticaria?
Urticaria, commonly known as hives, is a skin condition characterized by the appearance of itchy, raised, red welts (wheals) on the skin.
The pathophysiology of urticaria involves the release of histamine and other inflammatory mediators from mast cells, which are immune cells found in the skin and other tissues.
In acute urticaria, the release of histamine and other mediators is triggered by an allergic reaction to a specific allergen, such as food, medication, or insect sting.
This causes the mast cells to degranulate, releasing histamine and other mediators that cause blood vessels to become leaky, leading to the formation of wheals.
In chronic urticaria, the cause is often unknown, but it is thought to be related to an autoimmune mechanism.
In this case, the body produces autoantibodies that target the high-affinity IgE receptor (FcεRI) on mast cells, leading to their activation and the release of histamine and other mediators.
In both acute and chronic urticaria, the release of histamine and other mediators leads to the characteristic symptoms of itching, redness, and swelling.
Treatment typically involves the use of antihistamines to block the effects of histamine and reduce symptoms.
In severe cases, other medications such as corticosteroids or omalizumab may be used to control the condition.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['Rauta na']
['Na BioMedLib e vakayagataka na kompiuta (machine-learning algorithms) me bulia na taro kei na kena isau.']
['Eda tekivu ena 35 na milioni na ivola vakavuniwai e tabaki ena PubMed/Medline, kei na tabana ni RefinedWeb.']
